Exploration on the Mechanism of Shenqi Yiliu Prescription for Ovarian Cancer Based on Network Pharmacology,Molecular Docking and Experimental Validation
10.19879/j.cnki.1005-5304.202501257
- VernacularTitle:基于网络药理学、分子对接及实验验证探讨参芪抑瘤方治疗卵巢癌作用机制
- Author:
Lan MA
1
;
Yuping YANG
;
Min BAI
;
Zhining ZHANG
;
Yongqiang DUAN
Author Information
1. 宁夏医科大学总医院,宁夏 银川 750004
- Publication Type:Journal Article
- Keywords:
ovarian cancer;
Shenqi Yiliu Prescription;
network pharmacology;
molecular docking;
AKT-MDM2-P53 signaling pathway
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2025;32(7):42-48
- CountryChina
- Language:Chinese
-
Abstract:
Objective To predict the molecular mechanism of Shenqi Yiliu Prescription for the treatment of ovarian cancer based on network pharmacology and molecular docking technology;To conduct experimental validation.Methods The active components and targets of Shenqi Yiliu Prescription were retrieved and screened through TCMSP database,and ovarian cancer disease targets were searched through GeneCards database.A protein-protein interaction network between drugs and disease was established using the STRING database,and GO and KEGG pathway enrichment analysis was performed.Molecular docking between key active components and core targets was conducted.Ovarian cancer A2780 cells were intervened with Shenqi Yiliu Prescription low-,medium-and high-dosages containing serum.ELISA was used to detect TNF-α and IL-17 contents in cell supernatant;TUNEL staining was used to detect cell apoptosis;Western blot was used to detect the protein expressions of p-PI3K,p-AKT,phosphorylated T218(MDM2),and tumor protein P53(P53);real-time fluorescence quantitative PCR was used to detect the mRNA expressions of PI3K,AKT,MDM2 and P53.Results Network pharmacology analysis showed that quercetin,β-sitosterol and kaempferol were the active components of Shenqi Yiliu Prescription to treat ovarian cancer,and TP53,AKT1 and TNF were the core targets.The molecular docking results showed that the key active components could bind well to the core targets.KEGG enrichment analysis showed that the PI3K/AKT signaling pathway may be the core pathway for Shenqi Yiliu Prescription to intervene in ovarian cancer.The cell experiment results showed that compared with the control group,the contents of TNF-α and IL-17 in cell supernatant decreased(P<0.05),the apoptosis rate increased(P<0.05),the expressions of p-PI3K,p-AKT,MDM2 protein and PI3K,AKT,MDM2 mRNA decreased(P<0.05),and the expressions of P53 protein and mRNA decreased(P<0.05)in each Shenqi Yiliu Prescription group.Moreover,the intervention effect of Shenqi Yiliu Prescription was dose-dependent.Conclusion Shenqi Yiliu Prescription can effectively inhibit the proliferation and promote apoptosis of ovarian cancer cells,and its possible mechanism maybe related to inhibition of the activation of AKT-MDM2-P53 signaling pathway and the reduction of IL-17 and TNF-α contents.
